Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of HTL0030310 in Healthy Subjects
NCT03847207Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Jan 2019
- Primary completion
- Mar 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HTL0030310 in Cushing's disease (CD) and acromegaly (3 arms), sponsored by Nxera Pharma. Primary endpoints: Number of treatment related adverse events, Area under the effect time curve for hormones and 2 more. Started Jan 2019; status: completed.
02
Drugs
HTL0030310
03
Conditions
Cushing's disease (CD)acromegaly
Beyond the preview
Go deeper on NCT03847207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03847207.